The Supreme Court said Monday it will hear oral arguments in March in a high-profile case on the Food and Drug Administration‘s approval of a common abortion pill after a lower court put in place restrictions on how the drug can be used and distributed.

The case involves mifepristone maker Danco Laboratories and follows months of litigation after a federal district judge’s decision in Texas last April to suspend the FDA’s approval of the abortion drug.